INBX — Inhibrx Biosciences, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2024-05-29.
Performance
Technicals
Others in Healthcare
Measured signals that fired on INBX
| date | signal | measured base rate |
|---|---|---|
| 2026-07-20 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-05-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-22 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-04-17 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-04-01 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-03-30 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-10-07 | Shabet Rose Sharon | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | HALVORSEN OLE ANDREAS | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | Viking Global Opportunities Illiquid Investments Sub-Master LP | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | Viking Global Opportunities Portfolio GP LLC | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | Viking Global Opportunities GP LLC | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | Viking Global Opportunities Parent GP LLC | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | Ott David C. | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Open-market sale | 308.6K | 32.25 | 10.0M |
| 2025-10-07 | VIKING GLOBAL INVESTORS LP | Open-market sale | 25.0K | 32.25 | 807.6K |
| 2025-10-07 | HALVORSEN OLE ANDREAS | Open-market sale | 25.0K | 32.25 | 807.6K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| PERCEPTIVE ADVISORS LLC | 97.0M | 1.4M |
| VIKING GLOBAL INVESTORS LP | 96.7M | 1.4M |
| MORGAN STANLEY | 84.9M | 1.3M |
| Sanofi | 77.8M | 1.2M |
| HighTower Advisors, LLC | 58.5M | 870.2K |
| BlackRock, Inc. | 53.7M | 798.9K |
| STATE STREET CORP | 37.0M | 550.8K |
| VANGUARD CAPITAL MANAGEMENT LLC | 32.7M | 486.4K |
| Sofinnova Investments, Inc. | 27.3M | 406.0K |
| Capital Research Global Investors | 26.4M | 392.8K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Inhibrx Biosciences GAAP EPS of -$2.34 beats by $0.05 · 2026-08-13
- Inhibrx Biosciences, Inc. (INBX) filed form 8-K · 2026-08-13 · SEC EDGAR
- Inhibrx Reports Second Quarter 2026 Financial Results · 2026-08-13
Ask the AI about INBX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →